ALK and breast carcinoma: This is especially relevant in our country where almost half of breast cancer cases are diagnosed before age 50, and around 20% before age 40.[29] Moreover, multiple studies have shown that breast cancer in young women tends to be more aggressive, with higher proportions of aggressive molecular groups, especially the Basal-Like/Triple Negative (BL/TN) subtype.[30,31] It is therefore important to study the expression of ALK and CD30 in breast cancer in our population, particularly with the putative relationship between ALK expression and the BL/TN phenotype.[32]